The expansion of genomics into transplant medicine can provide improved diagnosis in
transplant candidates and potentially disease prediction in living donors. Transplant …

Atypical haemolytic uremic syndrome (aHUS) is a rare kidney disease due to a
dysregulation of the complement alternative pathway (AP). Complement factor I (CFI) …

Mutations in the complement factor H (CFH) gene are associated with complement
dysregulation and the development of atypical hemolytic uremic syndrome (aHUS). Several …

Recent progress in glomerular immune complex and complement-mediated diseases have
refined diagnostic categories and informed mechanistic understanding of disease …

Background Atypical hemolytic uremic syndrome (aHUS) is a rare, mostly complement-
mediated thrombotic microangiopathy. The majority of patients are infants. In contrast to …

Background Eculizumab has been approved for atypical haemolytic-uraemic syndrome
(aHUS) in Japan since 2013. Post-marketing surveillance enrolled patients with aHUS who …

Background. Hemolytic uremic syndrome (HUS) may present atypically without the full triad
of classical HUS. Eculizumab has been shown to be efficacious in complement-mediated …

Background and aim: Millions of people worldwide have suffered from coronavirus disease
2019 (COVID-19). COVID-19 can lead to coagulopathy and thrombosis, presenting as …

Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy
(TMA) which is considered life-threatening and caused by dysregulation of the complement …

Pediatric nephrology has rapidly evolved over the last several decades, with major
advances in the pathophysiology, genetics, diagnosis, and treatment of children with kidney …